ATE343400T1 - Verbindungen zur hemmung der angiogenese durch gentherapie - Google Patents

Verbindungen zur hemmung der angiogenese durch gentherapie

Info

Publication number
ATE343400T1
ATE343400T1 AT97945258T AT97945258T ATE343400T1 AT E343400 T1 ATE343400 T1 AT E343400T1 AT 97945258 T AT97945258 T AT 97945258T AT 97945258 T AT97945258 T AT 97945258T AT E343400 T1 ATE343400 T1 AT E343400T1
Authority
AT
Austria
Prior art keywords
vegf
tyrosine kinase
gene therapy
vegfs
nucleotide sequence
Prior art date
Application number
AT97945258T
Other languages
German (de)
English (en)
Inventor
Kenneth A Thomas Jr
Corey K Goldman
Richard L Kendall
William R Huckle
Andrew J Bett
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE343400T1 publication Critical patent/ATE343400T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT97945258T 1996-09-24 1997-09-24 Verbindungen zur hemmung der angiogenese durch gentherapie ATE343400T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2664196P 1996-09-24 1996-09-24

Publications (1)

Publication Number Publication Date
ATE343400T1 true ATE343400T1 (de) 2006-11-15

Family

ID=21833003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97945258T ATE343400T1 (de) 1996-09-24 1997-09-24 Verbindungen zur hemmung der angiogenese durch gentherapie

Country Status (9)

Country Link
US (1) US6375929B1 (enExample)
EP (1) EP0928203B1 (enExample)
JP (1) JP2001501471A (enExample)
AT (1) ATE343400T1 (enExample)
AU (1) AU738806B2 (enExample)
CA (1) CA2266419A1 (enExample)
DE (1) DE69736860T2 (enExample)
ES (1) ES2274549T3 (enExample)
WO (1) WO1998013071A1 (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723780D0 (en) * 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
WO2000024415A2 (en) 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
AU3755900A (en) * 1999-03-15 2000-10-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7653769B2 (en) * 2006-12-14 2010-01-26 International Business Machines Corporation Management of devices connected to infiniband ports
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
AUPQ592100A0 (en) * 2000-02-29 2000-03-23 Council Of The Queensland Institute Of Medical Research, The A method of treatment and prophylaxis
HUP0300810A2 (hu) 2000-07-20 2003-08-28 M.G.V.S. Ltd. Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
US7175658B1 (en) 2000-07-20 2007-02-13 Multi-Gene Vascular Systems Ltd. Artificial vascular grafts, their construction and use
WO2002024234A2 (en) * 2000-09-20 2002-03-28 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
GB0109781D0 (en) * 2001-04-20 2001-06-13 Oxford Biomedica Ltd Vector system
US20040062751A1 (en) * 2002-01-17 2004-04-01 Genetix Pharmaceuticals, Inc. Methods for inhibiting angiogenesis
AU2003215163A1 (en) * 2002-02-12 2003-09-04 Vanderbilt University Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
JP2007528355A (ja) * 2003-03-07 2007-10-11 アンジェスＭｇ株式会社 血管壁の炎症および新生内膜過形成を阻害する組成物および方法
US20060234969A1 (en) * 2003-03-07 2006-10-19 Anges Mg, Inc. Compositions and methods for inhibiting inflammation of vessel walls and formation of neointimal hyperplasia
JP2007525187A (ja) * 2003-05-16 2007-09-06 レセプター・バイオロジクス・インコーポレイテッド イントロン融合タンパク質、ならびにその同定方法および使用方法
US7358224B2 (en) 2003-05-29 2008-04-15 The University Of Manchester Class III SLRP agonists for the reduction of blood vessel formation
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
NZ601544A (en) 2003-08-27 2013-11-29 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
JP2008506366A (ja) * 2004-05-14 2008-03-06 レセプター バイオロジックス インコーポレイテッド 細胞表面受容体アイソフォームならびにその同定および使用方法
US20070224194A1 (en) * 2004-05-20 2007-09-27 Ludwig Institute For Cancer Research Methods for Inhibiting Angiogenesis and/or Lymphangiogenesis
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US7741515B2 (en) * 2004-09-02 2010-06-22 Eastman Chemical Company Optimized liquid-phase oxidation
US7586000B2 (en) * 2004-09-02 2009-09-08 Eastman Chemical Company Optimized liquid-phase oxidation
US7608732B2 (en) * 2005-03-08 2009-10-27 Eastman Chemical Company Optimized liquid-phase oxidation
US7563926B2 (en) * 2004-09-02 2009-07-21 Eastman Chemical Company Optimized liquid-phase oxidation
US7582793B2 (en) * 2004-09-02 2009-09-01 Eastman Chemical Company Optimized liquid-phase oxidation
US7910769B2 (en) * 2004-09-02 2011-03-22 Eastman Chemical Company Optimized liquid-phase oxidation
US7692037B2 (en) * 2004-09-02 2010-04-06 Eastman Chemical Company Optimized liquid-phase oxidation
US7683210B2 (en) * 2004-09-02 2010-03-23 Eastman Chemical Company Optimized liquid-phase oxidation
US7692036B2 (en) 2004-11-29 2010-04-06 Eastman Chemical Company Optimized liquid-phase oxidation
US7361784B2 (en) * 2004-09-02 2008-04-22 Eastman Chemical Company Optimized liquid-phase oxidation
US7504535B2 (en) * 2004-09-02 2009-03-17 Eastman Chemical Company Optimized liquid-phase oxidation
US7568361B2 (en) * 2004-09-02 2009-08-04 Eastman Chemical Company Optimized liquid-phase oxidation
US20060047153A1 (en) * 2004-09-02 2006-03-02 Wonders Alan G Optimized liquid-phase oxidation
US7390921B2 (en) * 2004-09-02 2008-06-24 Eastman Chemical Company Optimized liquid-phase oxidation
US7399882B2 (en) * 2004-09-02 2008-07-15 Eastman Chemical Company Optimized liquid-phase oxidation
US7381836B2 (en) * 2004-09-02 2008-06-03 Eastman Chemical Company Optimized liquid-phase oxidation
US7482482B2 (en) 2004-09-02 2009-01-27 Eastman Chemical Company Optimized liquid-phase oxidation
US7608733B2 (en) * 2004-09-02 2009-10-27 Eastman Chemical Company Optimized liquid-phase oxidation
US7507857B2 (en) * 2004-09-02 2009-03-24 Eastman Chemical Company Optimized liquid-phase oxidation
US7371894B2 (en) * 2004-09-02 2008-05-13 Eastman Chemical Company Optimized liquid-phase oxidation
US7589231B2 (en) * 2004-09-02 2009-09-15 Eastman Chemical Company Optimized liquid-phase oxidation
US7495125B2 (en) * 2004-09-02 2009-02-24 Eastman Chemical Company Optimized liquid-phase oxidation
WO2006031689A2 (en) 2004-09-13 2006-03-23 Genzyme Corporation Multimeric constructs
US20080206231A1 (en) * 2004-10-05 2008-08-28 Oregon Health And Science University Compositions and Methods for Treating Disease
EP1827602B1 (en) * 2004-11-26 2011-03-09 Novagali Pharma S.A. Modulating retinal pigmented epithelium permeaion by inhibiting vegfr-1
US20060116531A1 (en) * 2004-11-29 2006-06-01 Wonders Alan G Modeling of liquid-phase oxidation
WO2006081311A2 (en) * 2005-01-26 2006-08-03 Medical College Of Georgia Research Institute Compositions and methods for the intracellular disruption of vegf and vegfr-2 by intraceptors
WO2006088650A2 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
ZA200707258B (en) 2005-03-24 2008-06-25 Thromb X N V Novel anti-PLGF antibody
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
US7884232B2 (en) * 2005-06-16 2011-02-08 Eastman Chemical Company Optimized liquid-phase oxidation
EP1904095B1 (en) 2005-06-30 2013-05-29 VIB, vzw Treatment of liver cirrhosis and its complications
KR100737286B1 (ko) 2005-08-31 2007-07-13 박기랑 ＶＥＧＦＲ 트렁케이티드 ｃＤＮＡ를 함유하는 재조합아데노-연관 바이러스 및 이를 함유하는 암-특이적 유전자치료제
US7358389B2 (en) * 2006-01-04 2008-04-15 Eastman Chemical Company Oxidation system employing internal structure for enhanced hydrodynamics
US7355068B2 (en) 2006-01-04 2008-04-08 Eastman Chemical Company Oxidation system with internal secondary reactor
US9073997B2 (en) 2007-02-02 2015-07-07 Vegenics Pty Limited Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
US7871100B2 (en) * 2007-03-27 2011-01-18 Wonderland Nurserygoods Co., Ltd. Collapsible stroller
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
AU2009299744B2 (en) 2008-10-02 2015-08-20 Life Sciences Research Partners Vzw Inhibition of PLGF to treat Philadelphia chromosome positive leukemia
KR101248912B1 (ko) * 2009-12-31 2013-03-29 한양대학교 산학협력단 항혈관신생 활성을 가지는 재조합 아데노바이러스
HUE035554T2 (en) 2010-08-06 2018-05-02 Genzyme Corp VEGF antagonist compositions and their uses
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
PL2785739T3 (pl) 2011-12-01 2017-10-31 Thrombogenics Nv Poprawa wyniku trabekulektomii
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
AU2014218318B2 (en) 2013-02-18 2018-02-15 Vegenics Pty Limited Ligand binding molecules and uses thereof
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN106414474B (zh) 2014-03-17 2021-01-15 阿德夫拉姆生物技术股份有限公司 用于视锥细胞中增强的基因表达的组合物和方法
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
CA2978068C (en) 2015-03-02 2024-05-28 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
CN1701814A (zh) * 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
CA2158745C (en) * 1993-03-25 2007-06-19 Richard L. Kendall Inhibitor of vascular endothelial cell growth factor
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors

Also Published As

Publication number Publication date
CA2266419A1 (en) 1998-04-02
JP2001501471A (ja) 2001-02-06
WO1998013071A1 (en) 1998-04-02
DE69736860T2 (de) 2007-05-16
US6375929B1 (en) 2002-04-23
ES2274549T3 (es) 2007-05-16
AU4650397A (en) 1998-04-17
AU738806B2 (en) 2001-09-27
DE69736860D1 (de) 2006-12-07
EP0928203B1 (en) 2006-10-25
EP0928203A4 (en) 2003-01-22
EP0928203A1 (en) 1999-07-14

Similar Documents

Publication Publication Date Title
ATE343400T1 (de) Verbindungen zur hemmung der angiogenese durch gentherapie
Martiny-Baron et al. VEGF-mediated tumour angiogenesis: a new target for cancer therapy
Derynck TGF-β-receptor-mediated signaling
Goldman et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
Tejada et al. Tumor-driven paracrine platelet-derived growth factor receptor α signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma
Olofsson et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells
Feldkamp et al. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras
Wang et al. NRP-2 in tumor lymphangiogenesis and lymphatic metastasis
Reigstad et al. Structural and functional specificities of PDGF‐C and PDGF‐D, the novel members of the platelet‐derived growth factors family
Aase et al. Localization of VEGF‐B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature
Bachelder et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells
Guerrin et al. Vasculotropin/Vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultued in vitro
Sato et al. Properties of two VEGF receptors, Flt‐1 and KDR, in signal transduction a
Miyamoto et al. Heparin‐binding epidermal growth factor‐like growth factor as a novel targeting molecule for cancer therapy
Arevalo et al. TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor
Dow et al. Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions
EP1054687B1 (en) Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
Huang et al. Expression of VEGF and its receptors in different brain tumors
Tortora et al. Protein kinase A as target for novel integrated strategies of cancer therapy
Sledge Jr Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects
US7750138B2 (en) Angiogenesis-inhibiting chimeric protein and the use
Enholm et al. Vascular endothelial growth factor-C: a growth factor for lymphatic and blood vascular endothelial cells
Casscells et al. Mechanisms of restenosis
Das Epidermal growth factor: mechanisms of action
Chen et al. Roles of neuropilins in neuronal development, angiogenesis, and cancers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties